# SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

> **NCT07662395** · PHASE2,PHASE3 · RECRUITING · sponsor: **Sinocelltech Ltd.** · enrollment: 410 (estimated)

## Conditions studied

- Double Blind

## Interventions

- **DRUG:** SCTB41
- **DRUG:** Tislelizumab
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT07662395
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-09
- **Primary completion:** 2030-01-24
- **Final completion:** 2030-01-24
- **Target enrollment:** 410 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662395, "SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*